(87.2% vs 67.7%; P ¼ .001), and patients on dialysis (3.0% vs 0.0%; P ¼ .009, Table I ). There were fewer patients with comorbid coronary artery disease (32.3% vs 47.3%; P ¼ .005). The CC included more patients who had undergone prior aortoiliac endovascular intervention that had failed (17.3% vs 4.8%; P ¼ .0001), and there was a nonsignificant trend toward an increased number of patients undergoing AFB for critical limb ischemia (50.4% vs 40.7%; P ¼ .07) as opposed to claudication symptoms. Overall and major morbidity were similar in both cohorts (Table II) . Thirty-day mortality was similar and <1% in both cohorts, but 10-year survival was higher in the CC (67.7% vs 52.6%; P ¼ .02). Ten-year primary patency was higher in the HC (75.8% vs 90.8%; P ¼ .02), but secondary patency and limb salvage were similar in both cohorts, with the latter >95% in both cases.
Objectives:
The peroneal artery is a well-established target for bypass in patients with critical limb ischemia (CLI). The objective of this study was to compare the outcomes of peroneal bypass and endovascular peroneal intervention in terms of wound healing and limb salvage in patients with CLI.
Methods: Patients presenting between 2006 and 2013 with CLI (Rutherford IV-VI) and isolated peroneal runoff were included in the study. They were divided into patients who underwent bypass to the peroneal artery and those who underwent endovascular peroneal artery intervention. Demographics, comorbidities, and follow-up data were recorded. Wounds were classified by the Wound, Ischemia, foot Infection (WIfI) score. Primary end points included wound healing, amputation rate, and patency.
Results: Included were 200 limbs with peroneal bypass and 138 limbs with endovascular peroneal intervention, with mean follow-up of 24.0 6 26.3 and 14.5 6 19.1 months, respectively (P ¼ .0001). The two groups were comparable in comorbidities with the exception of the endovascular group having more patients with cardiac and renal disease and diabetes mellitus but fewer patients with smoking history. WIfI scores showed smaller, less severely infected wounds but more severe ischemia in the bypass group. The aggregate WIfI scores were similar between groups, as was the pedal runoff score (Table I) . Perioperatively, bypass patients had higher rates of myocardial infarction (4.5% vs 0%; P ¼ .012) and incisional complications (13.0% vs 4.4%; P ¼ .008). At 12 months, the bypass group compared to the endovascular group had better primary patency (47.9% vs 23.4%; P ¼ .002) and primary assisted patency (63.6% vs 42.2%; P ¼ .003) and a trend toward better secondary patency (74.2% vs 63.5%; P ¼ .11). There were no differences in the rate of reintervention (33.0% vs 42.0%; P ¼ .09), wound healing (52.6% vs 37.7%; P ¼ .14), or major amputation-free survival (81.5% vs 74.7%; P ¼ .38). In a multivariate analysis, neuropathy was associated with improved wound healing, while WIfI wound score, cancer, chronic renal insufficiency, and smoking were associated with decreased wound healing. Treatment modality was not a significant predictor (Table II) .
Conclusions: Endovascular peroneal artery intervention offers lower patency rates but improved perioperative morbidity and similar wound healing and limb salvage rates compared to peroneal bypass. In appropriately selected patients, endovascular intervention for isolated peroneal runoff is a low-risk intervention that may be sufficient to heal ischemic foot wounds and avoid limb loss.
Author Disclosures: O. Abdul-Malak: Nothing to disclose; E. Avgerinos: Nothing to disclose; A. Boitet: Nothing to disclose; R. Chaer: Nothing to disclose; E. Hager: Nothing to disclose; J. Henry: Nothing to disclose; M. Makaroun: Nothing to disclose; A. Mohapatra: Nothing to disclose. Objectives: An international panel of vascular access experts used the RAND Appropriateness Method (RAM) to develop criteria for upper extremity access procedure selection based on patient-specific factors (age, vascular anatomy, dialysis timing, body mass index [BMI], comorbidities). Their recently published work builds on the National Kidney Foundation Dialysis Outcome Quality Initiative (KDOQI) and, like KDOQI, is based on best available medical evidence and expert opinion. Given the large number of potential patient scenarios considered by the group, the publication did not result in a tool useful to the practitioner. Using the RAM project database, we developed a Vascular Access Procedure Selection (VAPS) mobile app that guides procedure selection, and we report the results of a study validating its use.
Methods: The records of 201 consecutive patients who underwent upper extremity arteriovenous fistula (AVF)/arteriovenous graft (AVG) placement (mean age, 57 years; male, 61%; mean BMI, 31 kg/m 2 ; catheter, 72%; diabetes mellitus, 61%) were retrospectively reviewed. Factors (vein/artery size, BMI, age, dialysis status, functional status) for each patient were entered into the VAPS mobile app, and the recommended and actual procedures were compared for each patient. The nonmaturation rates for AVF recommended by the VAPS mobile app were compared with AVF creations not recommended.
Results: The VAPS recommended an AVF as an appropriate procedure option in 170 of 201 patients (85%). The actual and recommended procedure matched in 117 patients (radiocephalic fistula, 55; forearm vein transposition, 2; brachiocephalic fistula, 46; basilic vein transposition, 14). In 53 cases where an AVF was recommended, an AVG was placed or a a Data are presented as mean 6 standard deviation or number (%).
